BACKGROUND AND PURPOSE: The spider-venom peptide PcTx1 is the most potent and selective inhibitor of acid-sensing ion channel (ASIC) 1a. It has centrally acting analgesic activity and is neuroprotective in rodent models of ischaemic stroke. Understanding the molecular details of the PcTx1 : ASIC1a interaction should facilitate development of therapeutically useful ASIC1a modulators. Previously, we showed that several key pharmacophore residues of PcTx1 reside in a dynamic β-hairpin loop; conclusions confirmed by recent crystal structures of the complex formed between PcTx1 and chicken ASIC1 (cASIC1). Numerous peptide : channel contacts were observed in these crystal structures, but it remains unclear which of these are functionally important. EXPERIMENTAL APPROACH: We combined molecular dynamics (MD) simulations of the PcTx1 : cASIC1 complex with mutagenesis of PcTx1 and rat ASIC1a. KEY RESULTS: Crystal structures of the PcTx1 : cASIC1 complex indicated that 15 PcTx1 residues form a total of 57 pairwise intermolecular contacts (<5 Å) with 32 channel residues. MD simulations, however, suggested that about half of these interactions do not persist in solution. Mutation to alanine of only eight of 15 PcTx1 contact residues substantially altered ASIC1a inhibition by PcTx1. Our data reveal that many of the peptide-channel interactions observed in the PcTx1 : cASIC1 crystal structures are not important for PcTx1 inhibition of rat ASIC1a. CONCLUSIONS AND IMPLICATIONS: We identified the atomic interactions that are critical for PcTx1 inhibition of ASIC1a. Our data highlight the value of combining structural information, MD and functional experiments to obtain detailed insight into the molecular basis of protein : protein interactions.
BACKGROUND AND PURPOSE: The spider-venom peptide PcTx1 is the most potent and selective inhibitor of acid-sensing ion channel (ASIC) 1a. It has centrally acting analgesic activity and is neuroprotective in rodent models of ischaemic stroke. Understanding the molecular details of the PcTx1 : ASIC1a interaction should facilitate development of therapeutically useful ASIC1a modulators. Previously, we showed that several key pharmacophore residues of PcTx1 reside in a dynamic β-hairpin loop; conclusions confirmed by recent crystal structures of the complex formed between PcTx1 and chickenASIC1 (cASIC1). Numerous peptide : channel contacts were observed in these crystal structures, but it remains unclear which of these are functionally important. EXPERIMENTAL APPROACH: We combined molecular dynamics (MD) simulations of the PcTx1 : cASIC1 complex with mutagenesis of PcTx1 and rat ASIC1a. KEY RESULTS: Crystal structures of the PcTx1 : cASIC1 complex indicated that 15 PcTx1 residues form a total of 57 pairwise intermolecular contacts (<5 Å) with 32 channel residues. MD simulations, however, suggested that about half of these interactions do not persist in solution. Mutation to alanine of only eight of 15 PcTx1 contact residues substantially altered ASIC1a inhibition by PcTx1. Our data reveal that many of the peptide-channel interactions observed in the PcTx1 : cASIC1 crystal structures are not important for PcTx1 inhibition of rat ASIC1a. CONCLUSIONS AND IMPLICATIONS: We identified the atomic interactions that are critical for PcTx1 inhibition of ASIC1a. Our data highlight the value of combining structural information, MD and functional experiments to obtain detailed insight into the molecular basis of protein : protein interactions.
Authors: Erin N Hoagland; Thomas W Sherwood; Kirsten G Lee; Christopher J Walker; Candice C Askwith Journal: J Biol Chem Date: 2010-10-29 Impact factor: 5.157
Authors: Miguel Salinas; Lachlan D Rash; Anne Baron; Gérard Lambeau; Pierre Escoubas; Michel Lazdunski Journal: J Physiol Date: 2005-11-10 Impact factor: 5.182
Authors: Natalie J Saez; Mehdi Mobli; Michael Bieri; Irène R Chassagnon; Alpeshkumar K Malde; Roland Gamsjaeger; Alan E Mark; Paul R Gooley; Lachlan D Rash; Glenn F King Journal: Mol Pharmacol Date: 2011-08-08 Impact factor: 4.436
Authors: Julie K Klint; Jennifer J Smith; Irina Vetter; Darshani B Rupasinghe; Sing Yan Er; Sebastian Senff; Volker Herzig; Mehdi Mobli; Richard J Lewis; Frank Bosmans; Glenn F King Journal: Br J Pharmacol Date: 2015-03-04 Impact factor: 8.739
Authors: Adam E Ziemann; Mikael K Schnizler; Gregory W Albert; Meryl A Severson; Matthew A Howard; Michael J Welsh; John A Wemmie Journal: Nat Neurosci Date: 2008-06-08 Impact factor: 24.884
Authors: Natalie J Saez; Evelyne Deplazes; Ben Cristofori-Armstrong; Irène R Chassagnon; Xiaozhen Lin; Mehdi Mobli; Alan E Mark; Lachlan D Rash; Glenn F King Journal: Br J Pharmacol Date: 2015-09-22 Impact factor: 8.739
Authors: Christian B Borg; Nina Braun; Stephanie A Heusser; Yasmin Bay; Daniel Weis; Iacopo Galleano; Camilla Lund; Weihua Tian; Linda M Haugaard-Kedström; Eric P Bennett; Timothy Lynagh; Kristian Strømgaard; Jacob Andersen; Stephan A Pless Journal: Proc Natl Acad Sci U S A Date: 2020-03-12 Impact factor: 11.205
Authors: Irène R Chassagnon; Claudia A McCarthy; Yanni K-Y Chin; Sandy S Pineda; Angelo Keramidas; Mehdi Mobli; Vi Pham; T Michael De Silva; Joseph W Lynch; Robert E Widdop; Lachlan D Rash; Glenn F King Journal: Proc Natl Acad Sci U S A Date: 2017-03-20 Impact factor: 11.205
Authors: Liam M Koehn; Natassya M Noor; Qing Dong; Sing-Yan Er; Lachlan D Rash; Glenn F King; Katarzyna M Dziegielewska; Norman R Saunders; Mark D Habgood Journal: F1000Res Date: 2016-07-26
Authors: Dmitry I Osmakov; Timur A Khasanov; Yaroslav A Andreev; Ekaterina N Lyukmanova; Sergey A Kozlov Journal: Front Pharmacol Date: 2020-07-08 Impact factor: 5.810